• Age ≥18 years to ≤ 75 years.

• Pathologic confirmed stage III or IV epithelial ovarian cancer, fallopian tube cancer or primary peritoneal carcinoma (EOC, PPC, FTC) or platinum sensitive, relapsed EOC, PPC or FTC (no more than 4 lines of therapy)

• Hepato-celiac lymph nodes metastases diagnosed by imaging before surgery and enlarged palpable lymph nodes by surgical findings

• Assessed by the experienced surgeons, complete resection is feasible according to preoperative evaluation

• 1 to 3 episodes of neoadjuvant chemotherapy is allowed in primary settings

• Platinum sensitive relapse is defined as those with platinum-free interval of 6 months or more.

• ASA score of 1 to 2

• ECOG performance status of 0 to 2

• Adequate bone marrow, liver and renal function to receive chemotherapy and subsequently to undergo surgery:

• White blood cells \>3,000/µL, absolute neutrophil count ≥1,500/µL, platelets ≥100,000/µL, hemoglobin ≥9 g/dL,

• Serum creatinine \<1.25 x upper normal limit (UNL) or creatinine clearance ≥60 mL/min according to Cockcroft-Gault formula or to local lab measurement

• Serum bilirubin \<1.25 x UNL, AST(SGOT) and ALT(SGPT) \<2.5 x UNL

• Comply with the study protocol and follow-up.

• Written informed consent.